„”
Dr.
Edgar Specker studied chemistry at the University of Münster, Germany. After his diplomacy thesis at the Bayer AG he received his PhD in 2004 as a member of Prof. Klebe´s research group at the University of Marburg. During his postdoctoral studies he joined the group of Prof. Bradley at the Universities of Southampton and Edinburgh. His professional career as medicinal chemist started at the biotech company Zedira GmbH in 2005 working on the synthesis of transglutaminase inhibitors to treat Celiac disease. In 2007, he moved to the Jerini AG and collaborated in a joined project with the company Alcon. Since 2010 he is responsible for the compound management at the FMP, at first in the Screening Unit and then as part of the medicinal chemistry group. Since the beginning of 2020 he is the head of the independent core facility compound management at the FMP and helped to build up the compound management for EU-OPENSCREEN ERIC over the last 3 years. He is one of the founders of the start-up company Trypto Therapeutics GmbH.
The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) is part of the Forschungsverbund Berlin e.V. (FVB), which legally represents seven non-university research institutes - members of the Leibniz Association - in Berlin.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10,
13125 Berlin, Germany
